Jilin Zhongke Bio-Engineering
Stem cell collection, preparation, and clinical transplantation.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | N/A | IPO | |
| Total Funding | 000k | ||
Jilin Zhongke Bio-engineering Co., Ltd (JZB) is a Chinese bio-engineering firm established in May 2007. Headquartered in Changchun City, Jilin Province, the company operates in the field of medical research and experimental development. Its core business encompasses stem cell collection, preparation for production, and clinical application of stem cell transplantation services. The company's services are applied in treating conditions such as cancer, diabetes, nerve damage, and autoimmune diseases, as well as for health and beauty purposes.
JZB reports having conducted over 3,000 clinical research cases and more than 10,000 stem cell transplant injections. It possesses the capacity for 10,000 stem cell frozen storage units per year and states its technology platform and equipment meet Level A standards in China. The company has attracted an international clientele, including patients from the US and Saudi Arabia, for its treatments. JZB also holds 12 patents. It is listed on the NEEQ stock exchange under the symbol 833207.
Keywords: stem cell therapy, bio-engineering, cell collection, clinical transplantation, regenerative medicine, medical research, autoimmune diseases, cell preparation, cell storage, biotechnology
